Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

Rhea-AI Summary

Aptose Biosciences Inc. (NASDAQ: APTO) announced that Dr. William G. Rice and CFO Mr. Fletcher Payne will attend the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 3:30 p.m. ET. Dr. Rice will present at the conference, and the management team will also hold one-on-one meetings. Aptose is focused on developing innovative oral kinase inhibitors for treating hematologic malignancies, with investigational products HM43239 and luxeptinib in clinical trials for conditions such as acute myeloid leukemia and B-cell malignancies.

SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, and Mr. Fletcher Payne, CFO of Aptose, will attend the Canaccord Genuity 42nd Annual Growth Conference, and Dr. Rice will present at the Conference:

Canaccord Genuity 42^nd Annual Growth Conference

Date:	Wednesday, August 10, 2022
Time:	3:30 p.m. ET
Webcast:	Link

The Aptose management team also will be hosting 1x1 meetings during the events.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Inc.	LifeSci Advisors, LLC
Susan Pietropaolo	Dan Ferry, Managing Director
Investor Relations	617-535-7746
201-923-2049	Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

FAQ

What is the date and time of the Canaccord Genuity 42nd Annual Growth Conference for Aptose?

The conference will take place on August 10, 2022, at 3:30 p.m. ET.

Who will represent Aptose at the Canaccord Genuity conference?

Dr. William G. Rice, Chairman and CEO, along with CFO Mr. Fletcher Payne, will represent Aptose.

What is Aptose Biosciences' focus in oncology?

Aptose focuses on developing personalized therapies for hematologic malignancies.

What are the investigational products developed by Aptose?

Aptose is developing HM43239, an oral myeloid kinase inhibitor, and luxeptinib, a dual lymphoid and myeloid kinase inhibitor.

What trials are ongoing for Aptose's products?

HM43239 is in a Phase 1/2 trial for relapsed or refractory acute myeloid leukemia, while luxeptinib is in Phase 1 a/b trials for various B-cell malignancies and AML.